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The objective of this study is to explore the extent to which managed care market
penetration in the United States is associated with the presence of chronic disease.
Diabetes was selected as the chronic disease of interest due to its increasing prevalence
as well as the disease management protocols that can lessen disease complications. We
hypothesized that greater managed care market penetration would be associated with (1)
lower prevalence of diabetes and (2) lower prevalence of diabetes-related comorbidities
(DRCs) among diabetics. Data for this analysis came from two sources. We merged
Medicare Advantage (MA) market penetration data from the Centers for Medicare and
Medicaid Services (CMS) with data from the Medical Expenditure Panel Survey (MEPS)
(2004–2008). Results suggest that county-level MA market penetration is not significantly
associated with prevalence of diabetes or DRCs. That finding is quite interesting in that
managed care market penetration has been shown to have an effect on utilization of
inpatient services. It may be that managed care protocols do not offer the same benefits
beyond the inpatient setting.
Keywords: cardiometabolic conditions, diabetes, cardiovascular disease, MEPS, Medicare Advantage, market
penetration, spillover effects
Introduction
Over the past 15 years, there has been a marked increase in the number of Medicare beneficiaries
enrolled in managed care plans. Medicare Advantage (MA) enrollment among Medicare beneficia-
ries has rapidly increased from 9% in 1995 to 30% in 2014 (1, 2). The market penetration rate of
MA varies from state to state and county to county, with urban areas having higher enrollment rates
(26%) compared to rural areas (15%) (3, 4).
Research on the effects of managed care penetration has primarily focused on inpatient care and
prevention services. Results indicate that increased managed care market penetration is linked to
higher rates of vaccinations and disease screenings among the general population (5–7). Greater
managed caremarket penetration is also associatedwith reduced utilization of unnecessary inpatient
procedures among Medicare beneficiaries (8, 9) reductions in inpatient complications (10) and
reduced mortality rates after hospital discharge (11, 12).
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The spillover effect of managed care processes is also of great
interest. Work in this area suggests that strategies implemented
by health care providers contracted with managed care organiza-
tions (MCOs) spillover to those providers’ patients who are not
members of MCOs, particularly in areas of high MCO market
penetration (5, 6, 9, 10). If spillover effects are truly impactful, it is
reasonable to posit that in areas with high MCO market penetra-
tion, physicians will identify chronic conditions more quickly and
prescribe treatment (and disease management), which may lead
to slower progression of disease (5, 9, 13–17).
The objective of this study is to explore the extent to which
managed caremarket penetration in theUnited States is associated
with the presence of chronic disease. Diabetes was selected as
the chronic disease of interest due to its increasing prevalence as
well as the disease management protocols that can lessen disease
complications.Wehypothesized that greatermanaged caremarket
penetration would be associated with (1) lower prevalence of dia-
betes and (2) lower prevalence of diabetes-related comorbidities
(DRCs) among diabetics.
Diabetes mellitus (DM) affects nearly 29.1 million (9.3%) peo-
ple in the United States, and costs the nation an estimated $245
billion annually (18). More than one in four Americans over the
age of 65 haveDM, and theirmorbidity contributes to the financial
strain on the Medicare and Medicaid programs (18, 19).
Improperly treated DM can result in elevated risk for other
DRCs, including vascular disease, neuropathy, renal disease,
retinopathy, and cardiovascular complications, such as stroke,
heart disease, coronary artery disease, and myocardial infarction.
Compared to a non-diabetic, an individual with DM has a two
to fourfold greater risk of dying from heart disease or having a
stroke (18).
Type 2 diabetes is often used as an example of a chronic
condition that can benefit from disease management tools often
used by managed care (20–22). When effectively implemented,
disease management protocols have reduced the rate of diabetes
and associated DRCs (23–30).
Materials and Methods
The data for this study were drawn from the Agency for Health-
care Research and Quality’s (AHRQ) Medical Expenditure Panel
Survey (MEPS) (31) and the Centers for Medicare and Medicaid
Services (CMS). CMS provided the MA market penetration data
(32, 33). MA market penetration is calculated by taking the num-
ber of MA enrollees in a county or state divided by the number of
Medicare beneficiaries in the same area. We merged MA market
penetration data with data for all Medicare beneficiaries in MEPS
from 2004 to 2008 (panels 9–12), based on each beneficiary’s
county of residence.
The MEPS household component (MEPS-HC) is a nationally
representative survey of non-institutionalized individuals residing
in households sampled from the previous year’s National Health
Interview Survey. The individuals followed in MEPS are grouped
into panels and surveyed five times (rounds) over 2 years. A
new panel begins each year, resulting in the overlapping panel
design (one panel’s first year is concurrent with the previous
panel’s second year) (31). After university institutional review
board approval, we used data from the non-public MEPS-HC (via
AHRQ’s secure data center), including information on individ-
uals’ and households’ demographics (including county and state
of residence), diagnoses, and coverage by Medicare and other
insurance.
In addition to standard exploratory data analysis, two multi-
variate logistic regression models were used to explore the associ-
ation between MAmarket penetration, diabetes, and DRCs at the
individual level. The key independent variable of interest, county-
level MA market penetration, was categorized into three groups:
<12.5, 12.5–24.9%, and25%. In establishing these groupings, we
considered previous research by Baker et al. (5) and Bundorf et al.
(8) with upward adjustment of the lower and middle categories
to account for the growth in MA market penetration nationwide
since the date of these publications.
Individual-level characteristics include race, gender, age, level
of education, income as a percent of federal poverty level (FPL),
urban residence (in a metropolitan statistical area), having other
insurance in addition to Medicare, and having a managed care
plan (34, 35).
In the first model, exploring the relationship between diabetes,
DRCs and MA market penetration, we retained the full sample
of 8089 Medicare beneficiaries in the 2004–2008 MEPS (pan-
els 9–12). The second model evaluates the association between
MA market penetration and the prevalence of DRCs among dia-
betic beneficiaries. In this model, individuals were selected who
reported diabetes at the end of the first (n= 1761) or second
(n= 1926) years of their panel. DRCs were defined using the
priority conditions inMEPS and included hypertension, coronary
heart disease (CHD), stroke or transient ischemic attack (TIA),
high cholesterol, diabetes-related eye or kidney disease, angina, or
heart attack (36, 37).
Survey procedures were used to allow for the complex sam-
pling design of MEPS. We used weights provided by MEPS to
ensure that the data were representative of the US civilian, non-
institutionalized Medicare population at the time the data were
collected. The weights were applied in both the descriptive analy-
sis and the logistic regression model, to adjust for non-response
and attrition, and in order to make estimates of person-level
changes in selected variables.
Results
Descriptive Analysis
The population for this study included 8089 Medicare beneficia-
ries who participated in MEPS between 2004 and 2008 (panels
9–12). The data had roughly equal representation from each of
the four panels. Women made up 56.6% of the sample, and 53%
were married (Table 1). Nearly 85% were identified as White, and
only 7% were Hispanic. Nearly one in five were under the age
of 65 (18.8%), which is slightly more than the national average
(17%), and one in five were at least 80 years of age. One-third
resided in a household with income higher than 400% of FPL.
While more than 25% did not receive a high-school education,
20% of the sample had a college education or greater. Nearly 80%
of respondents lived in urban areas (as defined by the US Census
Bureau). Slightly more than half had some insurance coverage
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TABLE 1 | Descriptive statistics.b
Variable N Percent Variable N Percent
Age groups Education
<50 612 6.48% Less than high school 2715 25.86%
50–64 1123 12.40% High school 2613 35.48%
65–69a 1922 24.14% Some college 1282 18.42%
70–74 1566 19.27% 4 years college 744 11.40%
75–79 1302 17.07% >4 years collegea 579 8.84%
80–84 936 12.40% Marital status
>85 628 8.24% Marrieda 4068 53.00%
Gender Managed care organization
Femalea 4616 56.62% Had MCO at the end of first yeara 1268 14.14%
Race Other insurance
Whitea 6287 84.77% Had other insurancea 3574 51.27%
Hispanic MA market penetration
Not Hispanica 7032 92.80% <12.5% 4741 57.70%
Income (% FPL) 12.5 to <25% 1218 16.47%
<100% FPL 1535 13.54% 25% or morea 2130 25.83%
100–125% 684 6.84%
126–200% 1458 17.27% Panel
201–399% 2186 29.02% Panel 9 (2004–2005)a 2017 24.37%
>400% FPLa 2222 33.33% Panel 10 (2005–2006) 2115 24.37%
Urban/rural Panel 11 (2006–2007) 2283 25.30%
Urbana 6248 79.28% Panel 12 (2007–2008) 1674 25.96%
aReference groups.
bAll percent statistics are weighted. N is unweighted.
besides Medicare. Fourteen percent had coverage throughMCOs.
Among Medicare beneficiaries, one in four resided in counties
with high MAmarket penetration (25%), and one in six resided
in areas of moderate MA market penetration (12.5–25% county
penetration).
Multivariate Logistic Regression Results
The main independent variable of interest is MA market pen-
etration. The results suggest that market penetration of man-
aged care (in the respondent’s county of residence) is not sig-
nificantly associated with individual-level diabetes or DRCs.
Respondent’s insurance type (private insurance in addition to
Medicare, and/or more specifically managed care member-
ship) is also not significantly associated with diabetes or DRCs
(Table 2).
Factors that appear to be significantly associated with diabetes
and DRC prevalence include race, reduced income, age, and place
of residence. The only variable in theweighted,multivariatemodel
that is significantly associated with DRCs among diabetics is place
of residence. Living in a rural area is significantly associated with a
reduced likelihood of diabetes andDRCs among the overallMEPS
Medicare beneficiary group.
However, rurality is strongly associatedwith an increased likeli-
hood of DRCs among diabetics. It may be that rural diabetics have
reduced access to specialty care, resulting in a greater likelihood
of DRCs.
The odds of having diabetes or a DRC increase with age and for
non-White individuals. Compared to respondents with household
incomes400% of FPL, a lower level of income increases the odds
of diagnosis. Although a significant relationship was observed
between diagnosis and income, no statistically significant rela-
tionship was observed between diagnosis and education.
Our analysis relies on publically available data and uses fairly
straightforward methods. It may be the case that in order to tease
out the effect thatMAmarket penetration has on diabetes a differ-
ent type of empirical analysis is needed. To this end, we developed
an alternative model that examined the association between MA
market penetration and the occurrence of new cases of diabetes
amongMedicare beneficiaries between year 1 (n= 1761) and year
2 (n= 1926).We excluded 1761 respondents who reported having
diabetes at the end of their first year in the MEPS panel. This
resulted in retention of 6328 (79.2%) of our original observations.
Like the other models in Table 2, the managed care market pen-
etration variable was not a significant factor in the likelihood of
being newly diagnosed with diabetes (results not shown in this
paper). The one interesting finding from this additional model
was that compared to beneficiaries between the ages of 65 and
70, respondents age 85 or older had less than half the odds of
being diagnosed with diabetes. This lower incidence of diabetes
in the oldest group of Medicare beneficiaries may be a survivor
effect (38, 39).
Discussion
In this study, we examined the associations between MA market
penetration and Medicare beneficiaries’ (1) diabetes and DRC
diagnoses overall and (2) DRCs among diabetics. This analysis is
one of the first since the passage of the Medicare Modernization
Act to address the role that market penetration of MA may have
on chronic disease and disease progression.
Although the empirical results do not support our hypotheses,
this study is important on two fundamental levels. The first relates
to whether “non-significant results” can tell a story. While our
results are not statistically significant, that finding in and of itself
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TABLE 2 | Odds ratios.a
Variables Odds ratios
Prevalence of diabetes and
diabetes-related comorbidities (DRCs) (n=8089)
Prevalence of DRCs
among diabetics (n=1926)
Market penetration <12.5% 1:19 0:996
Market penetration 12.5 to <25% 9:23 1:662
Non-White 1:258** 1:878
Hispanic 1:181 1:26
Federal poverty level (FPL) <100% 1:312 0:964
FPL 100–125% 0:986 0:927
FPL 126–200% 1:263 2:267
FPL 201–399% 1:234 1:334
Not married 0:987 1:47
Male 0:94 0:737
Less than high-school degree 1:195 1:541
High-school degree 1:162 0:722
Some college 1:199 1:414
4 years of college 0:975 0:663
Age<50 0:241*** 0:478
Age 50–64 1:084 0:988
Age 70–74 1:539*** 0:859
Age 75–79 1:732*** 0:968
Age 80–84 1:625*** 1:836
Age 85+ 1:696*** 1:167
No MCO 1:028 1:192
No other insurance 0:933 0:647
Not in MSA 0:787** 2:867**
*p<0.10; **p<0.05; ***p< 0.01.
aAll statistics are weighted.
is substantively significant. It is possible that the lack of association
between market penetration and diabetes is an indication that
managed care is not working as well as previous research has
indicated. It could also be the case that there are limited spillover
effects of managed care. Lastly, it could be that the protocols are so
varied in scope and implementation that no systematic impact can
be detected (i.e., more direct measures of the type and longevity of
disease management protocols within the individual plans). The
second contribution is methodological. We suggest researchers
use our study as a springboard for future work.
Limitations
While this study had unique strengths, there were limitations.
Screening rates influence the prevalence rates of diagnosed dis-
ease. Diabetes screening rates for this population were unavail-
able. Since screening rates are known to increase under man-
aged care (5–7), we expect that there is higher prevalence of
screening in areas of higher managed care market penetration,
all other things being constant. In the absence of a system-
wide model, the effect of changes in screening procedures and
rates on diabetes incidence and complications cannot be fully
ascertained.
We found significant results for rural Medicare beneficiaries.
However, given that most rural areas in the United States are pri-
mary care-shortage areas, it is possible that the rate of undiagnosed
diabetes and DRCs is higher in rural areas, and the prevalence of
diagnosed disease lower. The modest number of rural Medicare
beneficiaries in MEPS makes it difficult to understand the impact
of managed care market penetration. Future work will include
a larger population of rural individuals, and will focus on the
relationships between rurality and chronic disease.
The MEPS survey data are self-reported. With self-report data,
MEPS is subject to recall error and the honesty of participants’
responses to surveyors.
At a minimum, new work on the effects of managed care (or
specifically MA) market penetration on chronic diseases, such as
diabetes, should include the following:
(1) Representative data from all United States counties. In our
study, only a sample of United States counties is represented
in each MEPS panel. If these counties (or those not sampled)
are outliers on the distribution of MA market penetration,
this study’s findings may not be indicative of the true national
trends.
(2) Clinical data. Due to data limitations, our study relied on the
use of household-reported health information, not clinical
data. Clinical ormedical claims datamay reduce any problems
of recall bias and providemore precise diagnoses. In addition,
clinical data may be able to capture differences in clinical
severity of the underlying diagnoses and enable researchers
to consider the individual’s overall “disease portfolio.”
(3) At least 4 years of longitudinal data. In our study, disease
diagnosis variables were limited primarily to the priority con-
ditions questions in MEPS, which are asked only at the end
of each year (rounds 3 and 5), leaving only 1 year for new
diagnoses to be reported.
On balance, we do not take our results as the definitive
answer to the prevailing question: Does MA market penetration
Frontiers in Public Health | www.frontiersin.org October 2015 | Volume 3 | Article 2294
Howard et al. Medicare Advantage market penetration and diabetes
impact disease progression? Given that MAmarket penetration is
at 30%, and growing each year, future work in this area is essential
(40). The Affordable Care Act and various state reform efforts call
for innovative healthcare delivery models that bear similarities to
managed care. Understanding the role of MA market penetra-
tion (and managed care more broadly) is critical given that the
new delivery models are intended to improve population health
outcomes and reduce the incidence of chronic diseases.
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